ABSTRACT Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with a rising incidence largely driven by chronic liver disease. Accurate diagnosis and appropriate clinical assessment at the time of presentation are essential, as therapeutic strategies and prognosis depend on tumor burden, liver function, portal hypertension, and patient performance status. Aim: To develop evidence-based, multidisciplinary recommendations to guide the diagnosis, clinical assessment, and staging of patients with HCC. Methods: This consensus was developed by 43 experts from surgical oncology, hepatology, clinical oncology, radiology, interventional radiology, pathology, liver transplantation, gastroenterology, radiation oncology, and palliative care, under the coordination of the Brazilian Society of Surgical Oncology and 13 collaborating national medical societies. A scientific steering committee predefined clinically relevant questions addressing radiological and histopathological diagnosis, clinical assessment, diagnostic work-up, management of patients at the time of HCC diagnosis, and staging. These questions were discussed and refined in multidisciplinary meetings and submitted to structured voting rounds. Results: The panel formulated 18 recommendations covering key aspects of HCC evaluation, including standardized application of Liver Imaging Reporting and Data System (LI-RADS®) for imaging-based diagnosis, management of indeterminate lesions, indications for biopsy, histopathological classification and reporting, immunohistochemical markers, assessment of hepatic function and portal hypertension, staging systems, diagnostic work-up, and the role of multidisciplinary care. The recommendations emphasize integration of imaging findings with liver-related factors and clinical context to support individualized decision-making. Conclusions: This multidisciplinary consensus provides practical, evidence-based recommendations for the diagnosis, clinical assessment, and staging of HCC. By promoting standardized diagnostic practices while reinforcing comprehensive patient evaluation and multidisciplinary management, this document aims to improve diagnostic accuracy, optimize treatment selection, and support safe care.
F. Coimbra, André Luís de Godoy, P. H. de Sousa Fernandes et al.· Arquivos brasileiros de ciru...· 0 citations
Colorectal cancer (CRC) is the third most common malignant neoplasm worldwide and the second leading cause of cancer-related mortality. Currently, only about 15% of newly diagnosed CRC cases and 5% of metastatic cases are classified as being microsatellite instability-high (MSI-H) and can benefit significantly from immune checkpoint blockade, while the majority of patients are microsatellite stable (MSS) and typically show limited responses to this strategy. This review aims to describe recent advances and emerging perspectives regarding the use of novel checkpoint inhibitors for MSS CRC. We conducted a structured review and critical analysis of the most relevant evidence on immunotherapy in CRC. Particular focus was placed on response outcomes in MSS CRC populations treated with enhanced anti-CTLA-4 antibody botensilimab (BOT) and the anti-PD-1 antibody balstilimab (BAL). The combination of BOT+BAL has shown promising efficacy in heavily pretreated or refractory CRC, with objective response rates up to 20% and disease control rates around 60%. In the neoadjuvant setting, the BOT+BAL regimen has produced unprecedented pathologic complete response (pCR) rates for MSS CRC tumors, achieving a pCR rate of up to 40% and partial responses up to 71%. Treatment was associated with manageable toxicity and no surgical delays, resulting in downstaging levels that may spare surgery and/or adjuvant chemotherapy. Current evidence suggests a potential shift in the therapeutic landscape of CRC. Immunotherapy benefits may extend beyond MSI-H tumors, offering new possibilities for the broader population of patients with MSS CRC.
Thaís Sampaio Corrêa de Almeida, M. I. Braghiroli, J. Sabbaga et al.· American Journal of Clinical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.